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Effects of Smoking and Smoking
Cessation on Endothelial Function
1-Year Outcomes From a Randomized Clinical Trial
Heather M. Johnson, MD, Linda K. Gossett, MD, Megan E. Piper, PHD, Susan E. Aeschlimann,
Claudia E. Korcarz, DVM, Timothy B. Baker, PHD, Michael C. Fiore, MD, MPH,
James H. Stein, MD
Madison, Wisconsin
Objectives The purpose of this study was to determine whether smoking cessation improves flow-mediated dilation (FMD)
of the brachial artery.
Background The long-term effects of continued smoking and smoking cessation on endothelial function have not been
described previously.
Methods This was a 1-year, prospective, double-blind, randomized, placebo-controlled clinical trial of the effects of 5
smoking cessation pharmacotherapies. FMD was measured by B-mode ultrasonography before and 1 year after
the target smoking cessation date. Cessation was verified by exhaled carbon monoxide levels. FMD was com-
pared among study arms and between subjects who successfully quit smoking and those who continued to
smoke. Predictors of baseline FMD and FMD were identified by multivariable regression.
Results The 1,504 current smokers (58% female, 84% white) were 44.7  11.1 years of age and smoked 21.4  8.9
cigarettes/day. Baseline FMD was similar in each treatment arm (p  0.499) and was predicted by BA diameter
(p  0.001), reactive hyperemia blood flow (p  0.001), high-density lipoprotein cholesterol (p  0.001), and
carbon monoxide (p  0.012) levels. After 1 year, 36.2% quit smoking. FMD increased by 1% (6.2  4.4% to
7.2  4.2%) after 1 year (p  0.005) in those who quit, but did not change (p  0.643) in those who continued
to smoke. Improved FMD among quitters remained significant (p  0.010) after controlling for changes in bra-
chial artery diameter, reactive hyperemia, low-density lipoprotein cholesterol, and the presence of a home smok-
ing ban.
Conclusions Despite weight gain, smoking cessation leads to prolonged improvements in endothelial function, which may
mediate part of the reduced cardiovascular disease risk observed after smoking cessation. (Smoking Cessation
Medications: Efficacy, Mechanisms and Algorithms; NCT00332644) (J Am Coll Cardiol 2010;55:1988–95)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.002o
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dpidemiological studies have established strong relation-
hips between cigarette smoking, atherosclerosis burden,
nd cardiovascular disease (CVD) events; approximately
rom the University of Wisconsin School of Medicine and Public Health, Madison,
isconsin. This research was supported in part by grant P50 DA019706 from the
ational Institute on Drug Abuse to the University of Wisconsin–Center for Tobacco
esearch and Intervention. Drs. Johnson and Gossett were supported by the Ruth L.
irschstein National Research Service Award T32 HL07936 from the National Heart
ung and Blood Institute. Dr. Piper was supported by an Institutional Clinical and
ranslational Science Award KL2 RR025012. Medications for the study were
rovided by GlaxoSmithKline. Dr. Baker has received research grants from Pfizer,
laxoSmithKline, Nabi Biopharmaceuticals, and Sanofi. For the past 3 years, Dr.
iore has served as an investigator in research studies at the University of Wisconsin
hat were funded by Pfizer, GlaxoSmithKline, and Nabi Biopharmaceuticals. In 1998,
he University of Wisconsin appointed Dr. Fiore to a named Chair funded by an
nrestricted gift to the University of Wisconsin from Glaxo Wellcome.(
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010, accepted March 2, 2010.ne-third of smoking-related premature deaths are due to
VD (1–5). Significant CVD risk reduction and mortality
enefits are associated with smoking cessation (2,3,6,7).
igarette smoking promotes atherogenesis and CVD
hrough multiple interactive mechanisms including vasomo-
or, neurohormonal, and hematologic dysfunction, in-
reased oxidative stress, and dyslipoproteinemia; however,
he exact mechanisms are not fully understood (4,5).
Endothelial dysfunction is an early event in atherogenesis
hat results in inflammation, vasoconstriction, and throm-
osis (8,9). It has been hypothesized that endothelial cell
amage from inhaled cigarette smoke contributes to vascu-
ar injury, atherogenesis, and increased CVD risk; smoking
s few as 2 cigarettes/day doubles the number of nuclear-
amaged endothelial cells in the circulating blood
4,5,8,10–12). Flow-mediated vasodilation (FMD) of the
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May 4, 2010:1988–95 Smoking Cessation and Endothelial Functionrachial artery (BA) is a noninvasive, validated measure that
uantifies endothelial function and predicts future CVD
vents (13,14). In clinical and epidemiological studies,
moking-induced endothelial dysfunction seems to be dose
elated and may be reversible after smoking cessation
11,12,15). However, the mechanisms by which smoking
essation reduces CVD risk are unclear, and the long-term
ffects of continued smoking and smoking cessation on
ndothelial function have not been established. This study
valuated the effects of current smoking and smoking
essation on endothelial function in a prospective, random-
zed clinical trial of smoking cessation pharmacotherapy
16). We hypothesized that smoking cessation would im-
rove endothelial function of the BA.
ethods
tudy participants and design. The institutional review
oard at the University of Wisconsin School of Medicine
nd Public Health approved this study. All subjects pro-
ided written informed consent. This was a 3-year longitu-
inal, randomized, double-blind, placebo-controlled trial to
valuate the efficacy of 5 smoking cessation pharmacother-
pies and to examine the natural history of continued
moking and smoking cessation on subclinical atheroscle-
osis (16). This article describes the independent predictors
f BA FMD in current smokers at baseline, before smoking
essation treatment, and 1 year after the target quit date.
Participants were randomized to 1 of 6 treatment condi-
ions: nicotine lozenge, nicotine patch, sustained-release
upropion, nicotine patch plus nicotine lozenge, sustained-
elease bupropion plus nicotine lozenge, or placebo (Online
ppendix 1) (16). All participants received individual coun-
eling sessions (16). Major inclusion criteria were age 18
ears and older, smoking10 cigarettes/day, expired carbon
onoxide (CO) level 9 ppm, and stated motivation to
uit smoking. Major exclusion criteria were blood pressure
BP) 160/100 mm Hg, myocardial infarction within the
revious 4 weeks, heavy alcohol use, history of seizure or
erious head injury, use of contraindicated medications, and
urrent pregnancy or breastfeeding (16).
tudy procedures. Subjects were recruited from commu-
ities in and around Madison and Milwaukee, Wisconsin,
rom January 2005 to June 2007. The baseline clinical trial
isit included measurement of anthropometric data, fasting
aboratory tests, and completion of validated questionnaires
nd interviews. Physical activity was assessed by the Inter-
ational Physical Activity Questionnaire (17). Smoking
urden was evaluated by current cigarette smoking (ciga-
ettes/day) and pack-years (current cigarettes per day 
ears smoked). Recent smoke exposure was measured by an
xhaled CO level, which reflects smoking efficiency and
ecent smoke exposure. Smoking status was assessed by
elf-reported 7-day point-prevalence abstinence and was
onfirmed by an expired CO level of 10 ppm. Cotinine
as not used to assess abstinence because interventions in shis study included nicotine re-
lacement therapy, which could
ave produced false-positive re-
ults. When used with self-report
o indicate whether a person has
moked, CO and cotinine levels
how high agreement (18). Three
elf-reported measures of environ-
ental smoke exposure were eval-
ated at baseline: whether smok-
ng was allowed inside the home
home smoking ban), whether the
ubject lives with a partner/spouse
ho smokes, and whether smok-
ng was allowed in the workplace.
here is a strong relationship be-
ween self-reports of home and
ork smoke exposure and cotinine
evels (19). Fasting blood samples were obtained by venipunc-
ure and were refrigerated. Plasma aliquots were isolated by
entrifugation and frozen at 70°C.
easurement of BA reactivity. Endothelial function was
valuated by measuring the FMD of the BA in a core
ltrasound laboratory using a standardized protocol (13,20).
A reactivity studies were performed at baseline, before
nitiating therapy, and 1 year after the target quit date.
ubjects were required to be fasting and not use any
obacco-containing products for 8 h before the study.
ubjects were placed in a supine position in a temperature-
ontrolled room for 10 min before imaging. A BP cuff was
laced on the widest part of the proximal right forearm.
sing a 10-MHz linear array vascular ultrasound transducer
nd a Siemens Medical Solutions (Issaquah, Washington)
V70 ultrasound system, the BA was located above the
lbow and scanned in longitudinal sections. Extravascular
andmarks were identified and labeled to ensure reproduc-
bility within and between studies. After recording baseline
-mode ultrasound images of the BA and spectral Doppler
ltrasound images of flow, the cuff was inflated to 250 mm Hg
or 5 min to induce reactive hyperemia (RH). Immediately
fter deflation, spectral Doppler ultrasound images were
btained to verify hyperemia. BA images were obtained 60
nd 90 s later. Studies were recorded digitally; BA diameters
ere measured in triplicate with a digital border tracing tool
Access Point Web 3.0, Freeland Systems, Westfield, Indi-
na) by 3 readers blinded to subject information and
reatment. The same reader read the baseline and follow-up
tudies in all subjects. The primary outcome variable was the
aximum FMD (in %), the largest percentage of change in
he BA diameter after RH relative to the baseline diameter.
he absolute maximum FMD (in cm), the absolute differ-
nce in BA size after RH compared with baseline, also was
eported.
All sonographers completed a standardized certification
rogram. Ultrasound equipment was monitored using a
Abbreviations
and Acronyms
BA  brachial artery
BP  blood pressure
CO  carbon monoxide
CVD  cardiovascular
disease
FMD  flow-mediated
dilation
HDL-C  high-density
lipoprotein cholesterol
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
RH  reactive hyperemiamall-parts phantom. In our laboratory, subjects who un-
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Smoking Cessation and Endothelial Function May 4, 2010:1988–95erwent repeat FMD scans approximately 2 weeks apart
ad an interscan FMD difference of only 0.26% (0.43% to
0.72%, p 0.498); the median inter-reader variability was
0.14% to 0.09%, with correlations of 0.97 to 0.99 (p 
.001) (20). Re-evaluation of inter-reader and intrareader
ariability in 2009 showed similar, small mean FMD differ-
nces between the 2 readers evaluated (0.13% to 0.26%).
ata analysis. All analyses were performed with SPSS
oftware (Version 17.0, SPSS, Inc., Chicago, Illinois).
ontinuous variables are given as mean (SD); categorical
ariables are presented as percentages. Differences in base-
ine BA diameter and maximum FMD between the treat-
ent conditions were evaluated using univariate analysis of
ariance and Tukey’s test. Because treatment condition was
ot significantly related to the dependent variables, it was
ot covaried in further baseline analyses. Pearson correla-
ions were used to identify univariate predictors of BA
iameter and FMD. Partial correlations controlling for BA
iameter were obtained for baseline FMD. Using candidate
ariables (p  0.10) from partial correlations, multivariate
nalyses were performed to determine variables that were
ndependently associated with baseline FMD, before the ini-
iation of smoking cessation pharmacotherapy. Because base-
ine BA diameter was such a strong predictor of baseline
MD, all models were adjusted for BA diameter and reader.
ecause sex was strongly correlated with baseline diameter,
eparate analyses were performed for men and women.
The mean difference in the BA diameter (in cm) and the
bsolute FMD (in %) from baseline to 1 year after the
arget quit date were analyzed. t tests were used to evaluate
ifferences between subjects who did and did not return for
ubject Characteristics at Baseline and 1 Year After the Target QuTable 1 Subject Characteristics at Baseline and 1 Year After t
All Subjects,
Baseline
Relapsed
Baseline,
Mean (SD)
1 Yr,
Mean (SD)  (SD
n 1,504 1,125 589
Body mass index (kg/m2) 29.0 (6.5) 28.9 (6.5) 29.0 (6.4) 0.24 (1
Waist circumference (cm) 95.9 (16.2) 95.5 (15.9) 96.1 (15.8) 0.99 (6
CO (ppm) 25.7 (12.4) 26.5 (12.7) 19.1 (12.1) 7.2 (1
Heart rate (beats/min) 62.9 (10.5) 74.2 (9.6) 71.4 (9.8) 2.0 (1
Systolic BP (mm Hg) 124.9 (14.7) 119.0 (14.5) 116.6 (14.5) 2.8 (1
Diastolic BP (mm Hg) 74.0 (9.4) 74.1 (10.2) 72.3 (10.1) 1.6 (9
Total cholesterol (mg/dl) 183.9 (35.4) 183.4 (36.0) 183.6 (37.5) 0.8 (2
LDL-C (mg/dl) 118.9 (30.6) 118.2 (31.0) 119.3 (32.3) 0.38 (2
HDL-C (mg/dl) 42.0 (13.5) 42.0 (13.5) 42.7 (14.4) 0.4 (8
Triglycerides (mg/dl) 143.3 (101.7) 144.1 (107.9) 134.5 (100.4) 10.0 (8
Fasting glucose (mg/dl) 94.9 (17.7) 95.3 (18.7) 97.2 (23.1) 0.9 (1
HbA1c (%) 5.6 (0.6) 5.6 (0.7) 5.73 (0.760) 0.12 (0
hsCRP (mg/l) 2.11 (11.0) 2.22 (12.6) 3.98 (7.70) 2.06 (7
Baseline BA diameter (cm) 0.395 (0.073) 0.393 (0.072) 0.403 (0.072) 0.005 (0
Baseline flow (ml/min) 116.8 (76.8) 117.1 (78.5) 127.5 (80.4) 11.4 (7
RH blood flow (ml/min) 686.8 (269.3) 679.5 (269.7) 719.5 (263.6) 39.8 (2
Absolute FMD (cm) 0.023 (0.015) 0.023 (0.015) 0.025 (0.014) 0.001 (0
FMD (%) 6.15 (4.35) 6.48 (4.26) 6.58 (4.05) 0.04 (4A  brachial artery; BP  blood pressure; CO  carbon monoxide; FMD  flow-mediated dilation; HbA1
ipoprotein cholesterol; RH  reactive hyperemia.he 1-year FMD visit. Next, we conducted a series of
nivariate analyses of variance to test for differences among
he treatment conditions on 2 dependent variables: changes in
aseline diameter and maximum FMD from baseline to year 1.
ecause treatment condition was not significantly related to
he dependent variables, it was not covaried in later analyses.
he t tests were used to evaluate differences in FMD and
BA diameter by sex and within and between groups who quit
moking versus those who continued smoking. Multivariate
egression analyses were used to determine variables that
ndependently predicted FMD at 1 year after the target quit
ate. All models were adjusted for BA diameter and reader.
aseline variables and changes in variables from baseline to
ear 1 were considered in the FMD analysis.
All variables were examined with regard to their distri-
utional properties by visual inspection and assessment of
urtosis and skew. Four variables were not normally distrib-
ted: pack-years, triglycerides, high-sensitivity C-reactive
rotein (hsCRP), and baseline BA flow. These values were
og-transformed and comparisons were repeated, but com-
arable results were seen. Log-transformed values of these
ariables were retested in the multivariate models, and no
ajor changes were observed. Residual plots from all
eported regression models were inspected and seemed to be
ormally distributed.
esults
ubject characteristics. Subject characteristics at baseline
nd after 1-year follow-up are shown in Table 1. Baseline
tudies were performed in 1,504 current smokers before
terget Quit Date
Abstained p Values
Baseline,
Mean (SD)
1 Yr,
Mean (SD)  (SD)
Baseline, Relapsed
vs. Abstainer
, Relapsed
vs. Abstainer
379 334
29.0 (6.6) 30.5 (6.7) 1.61 (2.04) 0.842 0.001
97.1 (16.9) 100.0 (16.0) 3.05 (10.67) 0.103 0.002
23.6 (11.4) 2.1 (1.9) 21.3 (11.2) 0.001 0.001
73.1 (9.6) 69.6 (9.3) 3.3 (10.7) 0.049 0.089
120.6 (14.2) 116.5 (14.9) 4.4 (14.6) 0.066 0.102
75.1 (9.5) 73.7 (10.7) 1.4 (10.4) 0.091 0.744
185.4 (33.5) 185.8 (34.9) 1.3 (28.2) 0.355 0.273
121.0 (29.5) 119.3 (31.2) 0.81 (24.2) 0.144 0.449
41.9 (13.6) 44.9 (13.6) 2.8 (8.3) 0.927 0.001
140.9 (80.7) 138.3 (90.4) 0.1 (75.2) 0.601 0.065
94.2 (13.7) 98.5 (26.9) 4.3 (22.7) 0.299 0.008
5.6 (0.5) 5.69 (0.631) 0.14 (0.42) 0.788 0.543
1.72 (2.94) 3.89 (5.42) 2.22 (5.77) 0.454 0.715
0.402 (0.074) 0.409 (0.074) 0.006 (0.019) 0.054 0.565
116.2 (71.4) 135.5 (132.8) 19.6 (128.0) 0.863 0.263
708.8 (267.4) 766.9 (295.6) 48.8 (268.4) 0.089 0.626
0.024 (0.015) 0.028 (0.015) 0.004 (0.017) 0.210 0.017
6.15 (4.36) 7.20 (4.18) 1.00 (4.30) 0.391 0.005it Dahe Ta
)
.73)
.36)
3.0)
0.7)
3.5)
.9)
8.8)
2.2)
.7)
0.4)
6.1)
.50)
.07)
.020)
0.0)
28.8)
.015)
.46)c  glycosylated hemoglobin; HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density
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May 4, 2010:1988–95 Smoking Cessation and Endothelial Functionnitiating therapy. Subjects (58.2% female, 83.9% white,
3.6% African American) were 44.7 11.1 years of age and
moked 21.4 8.9 cigarettes/day with a smoking burden of
9.4  20.4 pack-years. These values did not differ between
harmacotherapy treatment arms. They consumed 16.0 
3.9 alcohol-containing beverages per month and per-
ormed 122.0  150.1 MET (metabolic equivalent)-h/day
f moderate-vigorous and 11.1  21.4 MET-h/day of
eisure activity. Regarding environmental smoke exposure,
7.9% lived with a spouse/partner who smoked, 46.3% had
home smoking ban, and 51.4% had smoking bans at work.
aseline FMD was 6.2  4.4% and the BA diameter was
.40  0.07 cm. Baseline FMD (p  0.297), BA diameter
p  0.424), BA blood flow (p  0.146), and RH flow
p  0.640) did not differ among pharmacotherapy treat-
ent arms.
valuation of baseline FMD and BA diameter. Baseline
MD correlated significantly (p  0.001) with age (r 
0.14), systolic BP (r  0.11), diastolic BP (r  0.15),
igarettes smoked per day (r  0.09), current pack-years
r0.13), creatinine (r0.11), glucose (r0.07, p
.017) and hsCRP (r  0.06, p  0.027). The strongest
orrelation was between BA diameter and FMD (r 
0.34, p  0.001); therefore, partial correlations (adjusting
or BA diameter) with baseline FMD were identified and
ncluded RH flow (radj  0.343, p  0.001), cigarettes
moked per day (radj  0.10, p  0.019), current pack-
ears (radj  0.12, p  0.005), hsCRP (radj  0.12, p 
.005), and high-density lipoprotein cholesterol (HDL-C)
radj  0.16, p  0.001).
BA diameter (p  0.001), RH flow (p  0.001), CO
p  0.012) and HDL-C (p  0.001) were independently
Independent Associations With Maximum FMDat Baseline in All Subjects (R2adj  0.225)Table 2 Independent Associations With Maxat Baseline in All Subjects (R2adj 
Beta Standardiz
Constant 19.107 —
BA diameter (cm) 35.049 0.5
RH blood flow (ml/min) 0.006 0.3
HDL-C (mg/dl) 0.030 0.0
CO (ppm) 0.025 0.0
Reader 0.585 0.1
Abbreviations as in Table 1.
Independent Associations With Maximum FMDi Men at Baseline (R2adj  0.237)Table 3 Indep ndent Associations With Maxin Men at Baseline (R2adj  0.237)
Beta Standardiz
Constant 17.789 —
BA diameter (cm) 33.226 0.4
RH blood flow (ml/min) 0.004 0.3
Triglycerides (mg/dl) 0.002 0.0
Reader 0.589 0.1Abbreviations as in Table 1.ssociated with baseline FMD (R2adj  0.225) (Table 2).
model of baseline FMD without RH flow resulted in
he same predictors but with a lower R2adj (0.142)
Online Appendix 2). Models using absolute FMD (in cm)
s an outcome variable identified similar predictors, but
ith a lower R2adj (0.152). Men had larger BA diameters
0.46  0.06 cm vs. 0.35  0.05 cm, p  0.001) and waist
ircumferences (101.1  14.6 cm vs. 92.2  16.3 cm, p 
.002) than women, as well as lower FMD (5.5  3.7%
s. 6.7  4.7%, p  0.001). In men (Table 3), FMD was
ndependently associated with BA diameter (p  0.001)
nd RH flow (p  0.001), with a trend for triglycerides
p  0.058). In women (Table 4), FMD was indepen-
ently associated with BA diameter (p  0.001), RH
ow (p  0.001), and CO (p  0.011), with a trend for
DL-C (p  0.061).
Because BA diameter was consistently associated with
MD and has been shown to predict CVD events as well as
MD (14,21), associations with BA diameter were identi-
ed. Significant (p  0.005) correlations for BA were seen
ith body mass index (r  0.24), waist circumference (r 
.42), systolic BP, diastolic BP, age, cigarettes smoked per
ay, pack-years, creatinine, glucose, hematocrit, HDL-C,
riglycerides, physical activity, and C-reactive protein (p 
.029). BA diameter (Table 5) was independently associated
ith male sex (p  0.001), age (p  0.001), waist circum-
erence (p  0.001), glucose (p  0.018), and physical
ctivity (p  0.001).
redictors of maximum FMD 1 year after target quit
ate. Smoking status was available for the 923 (61.4%)
ubjects who attended the 1-year follow-up visit, of whom
34 (36.2%) successfully quit smoking (abstainers). Subjects
FMD (%)
5)
ta
95% Confidence Interval
padjLower Limit Upper Limit
17.228 20.985 0.001
39.183 30.915 0.001
0.005 0.007 0.001
0.048 0.012 0.001
0.044 0.005 0.012
0.854 0.317 0.001
FMD (%)
ta
95% Confidence Interval
padjLower Limit Upper Limit
15.104 20.474 0.001
39.234 27.219 0.001
0.003 0.005 0.001
0.000 0.005 0.058
0.950 0.227 0.001(%)imum
0.22
ed Be
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95
69
18(%)imum
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Smoking Cessation and Endothelial Function May 4, 2010:1988–95ho did not return for the 1-year visit were 1 year older than
hose who returned (p  0.032) and more likely to be male
p  0.032), but did not differ in race (p  0.365) or
aseline cigarettes smoked per day (p 0.357). On average,
aseline FMD was lower among subjects who did not return
5.8  4.5% vs. 6.5  4.2%, p  0.005).
After 1 year, abstainers gained more weight (4.6  5.7 kg)
han continuing smokers (0.7  5.1 kg, p  0.007) and had
arger waist circumferences (100.0 16.1 cm vs. 96.1  15.8
m, p  0.001). There were no significant differences in
hange in C-reactive protein (p  0.715) or change in
ow-density lipoprotein cholesterol (LDL-C) (p  0.449).
FMD was similar in men (0.2 3.8%) and women (0.5
.9%, p  0.336). Changes in baseline BA diameter
p  0.701) and FMD (p  0.499) did not differ signifi-
antly among treatment arms.
Among subjects who quit smoking, FMD increased from
.2  4.4% to 7.2  4.2% after 1 year (p  0.005) (Fig. 1).
mong subjects who continued smoking, the change in
MD from 6.5  4.3% to 6.6  4.1% was not significant
p  0.643). BA diameter, BA flow, and RH flow did not
hange among or between abstainers and continuing
mokers. Independent predictors of change in FMD after
year were abstinence from cigarette smoking (p  0.010),
BA diameter (p  0.001), RH flow (p  0.001),
LDL-C (p 0.004), and a home smoking ban (p 0.04)
R2adj  0.284) (Table 6).
Regarding environmental smoke exposure, only the pres-
nce of a home smoking ban predicted FMD. Adding the
resence of a home smoking ban to the multivariate model
Independent Associations With Maximum FMDi Women at Basel ne (R2adj 0.240)Table 4 Independent Associations With Maxin Women at Baseline (R2adj 0.24
Beta Standardiz
Constant 23.297 —
BA diameter (cm) 52.475 0.5
RH blood flow (ml/min) 0.008 0.3
CO (ppm) 0.036 0.0
HDL-C (mg/dl) 0.024 0.0
Reader 0.527 0.1
Abbreviations as in Table 1.
Independent Associations With BA Diameter inat Baseline (Cross-Sectional Analysis, R2adj  0Table 5 Independent Associ tions Wi h BAat Baseline (Cross-Sectional Analys
Beta Standar
Constant 0.291
Male sex 0.089 0
Age (yrs) 0.001 0
Waist circumference (cm) 0.001 0
Glucose (mg/dl) 0.000 0
Physical activity (MET-h/day) 0.004 0
Reader 0.002 0BA  brachial artery; MET  metabolic equivalent.ttenuated the effect of abstinence on FMD slightly
Online Appendix 3); however, there was no significant
nteraction between a home smoking ban and smoking
essation (p  0.304). Baseline smoking burden (cigarettes/
ay) did not affect the change in FMD after cessation;
FMD did not differ between quartiles of cigarettes per
ay, and baseline cigarettes per day was not an independent
redictor of FMD (p  0.304) (Online Appendix 4).
ther than the home smoking ban, none of the baseline
ariables, including age and sex, predicted FMD after 1
ear. Multivariate models showed no significant associations
etween FMD and changes in the following variables:
-reactive protein, body mass index, waist circumference,
lucose, and HDL-C. BA diameter was a strong predictor
f FMD in all models; models of FMD without BA
iameter had a much lower R2adj (0.040).
iscussion
his was the largest prospective, randomized clinical trial to
ate that evaluated the effects of smoking cessation and
ontinued smoking on endothelial function. Individuals
ho stopped smoking experienced a significant improve-
ent in endothelial function, despite gaining weight. The
ross-sectional and longitudinal components of this study
ighlight important pathophysiological relationships among
igarette smoking, arterial dysfunction, and risk factors for
VD among current smokers and individuals who quit
moking.
FMD (%)
ta
95% Confidence Interval
padjLower Limit Upper Limit
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nt Smokers)e er in Cu rent Smokers
2
adj  0.567)
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0.001 0.001 0.001
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May 4, 2010:1988–95 Smoking Cessation and Endothelial FunctionThe improvement in FMD 1 year after smoking cessation
hat we identified is consistent with that of a previous report
rom a smaller, observational cohort study (11). The rela-
ionship between abstinence and improved FMD that we
dentified remained significant even after adjusting for
hanges in BA diameter and RH blood flow. Although BA
iameter and BP did not significantly change with absti-
ence, heart rate was numerically lower in abstainers com-
ared with continuing smokers, so it is possible that
moking affected vasomotor tone.
A sentinel finding in our study is that FMD improved
mong abstainers, despite weight gain. Abstainers gained
ignificantly more weight and had larger waist circumfer-
nces after 1 year than did continuing smokers, consistent
ith previous findings (22). Although increases in central
diposity are associated with adverse CVD risk factors and
ndothelial dysfunction, in regard to FMD, the salutary
ffects of smoking cessation seemed to outweigh the adverse
ffects of weight gain. However, weight gain may explain
he absence of a significant difference in hsCRP between
bstainers and continuing smokers.
Figure 1 Absolute FMD Values 1 Year After Quit Date,
Expressed as Percentages
Solid horizontal bars represent means, dashed horizontal bars represent medi-
ans. Box margins are the 25th and 75th percentiles. Whiskers are the 10th
and 90th percentiles. Dots are the 5th and 95th percentiles. FMD  flow-
mediated dilation.
Predictors of Change in FMD (%), 1 Year After TTable 6 Predictors of Change in FMD (%), 1
Beta S
Constant 1.237
Abstinence status after 1 yr 0.848
Change in baseline BA diameter (cm) 107.944
Change in RH blood flow (ml/min) 0.005
Change in LDL-C (mg/dl) 0.020
Environmental smoke exposure
(home smoking ban)
0.661
Reader 0.025Abbreviations as in Table 1.The 1% absolute increase in FMD among smokers is not
s dramatic as that reported with statins and other inter-
entions (13); however, it is well within the measurement
ariability of our laboratory (20). In contrast to most statin
tudies of FMD, our study population was heterogeneous
nd included individuals with a higher risk factor burden
smoking, overweight, low HDL-C), some of which im-
roved (smoking, HDL-C) and some of which worsened
overweight) over time. Also, our treatment effect may be
nderestimated because subjects who quit smoking may still
e exposed to environmental cigarette smoke. An approxi-
ate 1% difference in FMD is associated with a significantly
ower rate of incident CVD events (14). Extended
ollow-up would be necessary to evaluate the relationship
etween FMD changes 1 year after smoking cessation and
uture CVD events.
The presence of a home smoking ban was associated with
reater improvement in FMD; however, it did not signifi-
antly interact with the effect of abstinence on FMD.
herefore, environmental restrictions on smoke exposure
nd an individual’s successful smoking cessation both con-
ribute to improvement in FMD. Further research should
nclude biochemical measures of environmental smoke ex-
osure. Reductions in LDL-C also predicted improvement
n FMD. Elevated LDL-C is a risk factor for CVD, and
hanges in LDL-C are associated with changes in FMD
21). Although smoking status did not influence LDL-C,
DL-C can change over time due to diet, aging, and
edication use. Because of our large sample size, we were
ble to detect changes in FMD related to changes in
DL-C over 1 year. Importantly, baseline markers of
moking intensity and baseline CVD risk factors did not
redict changes in FMD after 1 year, suggesting that
hanges in behaviors associated with smoking and LDL-C
nfluence CVD risk. Mechanistically, endothelial nitric
xide synthase seems to promote release of endothelial
rogenitor cells from the bone marrow (23). Improved
MD of the BA, as seen in our study, is nitric oxide
ependent (9,14). It is likely that smoking cessation reduces
xidative damage to endothelial cells, increases nitric oxide
vailability, and increases mobilization of endothelial pro-
t Quit Date (R2adj  0.284)r After Target Quit Date (R2adj  0.284)
dized Beta
95% Confidence Interval
padjLower Limit Upper Limit
— 0.033 2.440 0.044
0.091 0.207 1.489 0.010
0.468 123.951 91.938 0.001
0.277 0.006 0.004 0.001
0.103 0.033 0.006 0.004
0.073 1.291 0.031 0.040
0.005 0.290 0.340 0.877argeYea
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Smoking Cessation and Endothelial Function May 4, 2010:1988–95enitor cells from the bone marrow, indicating arterial
epair and reduction in CVD risk (4,9,10).
Endothelial dysfunction is one of several mechanisms
y which cigarette smoking promotes atherosclerosis
4,5,8,9,11,12). In our cross-sectional analysis of 1,500
ndividuals who smoked at least 10 cigarettes/day, HDL-C
nd CO levels significantly predicted FMD, an established
easure of endothelial function that predicts future CVD
vents (9,13,14); however, BA diameter was the most
owerful predictor of FMD, accounting for most of the
ariance in FMD in current smokers. Independent predic-
ors of baseline BA diameter included age, male sex, waist
ircumference, glucose, and physical activity. These findings
re consistent with those of previous reports showing that
A diameter is strongly associated with CVD risk factors
nd predicts CVD events (14,21). Although BA diameter is
he strongest predictor of FMD in smokers, BA diameter
eems to reflect the influence of additional CVD risk
actors that contribute to endothelial dysfunction and
therogenesis.
We found strong positive correlations among BA diam-
ter, waist circumference, and body mass index, as well as
arger BA diameters among men compared with women.
MD in male smokers was predicted by BA diameter and
riglycerides, a component of metabolic syndrome. In
omen, FMD was predicted by BA diameter and low
DL-C, which also is a component of metabolic syndrome
nd a predictor of CVD. To determine whether BA
iameter was masking other significant predictors of FMD,
e created separate models without BA diameter and found
he expected directional relationships among FMD, age,
ex, and CO; however, no other CVD risk factors were
ndependently associated with FMD. These models ac-
ounted for less variance than did those that included BA
iameter. The confounding relationship between BA size
nd body size in studies of FMD has been described
reviously (24,25). Patients with metabolic syndrome have
arger BA diameters than those without (25). The inverse
elationship between HDL-C and baseline FMD that we
bserved in our multivariate models most likely was due to
ntercorrelations between HDL-C, body size (waist circum-
erence, male sex), and BA diameter.
In regard to smoking parameters, CO, a measure of
moking heaviness, was independently associated with base-
ine FMD, but measures of smoking quantity such as
igarettes per day and pack-years were not. Previous reports
ad conflicting conclusions about a dose-response relation-
hip between cigarette smoking and CVD risk (4,5). Our
tudy suggests that an objective measure of smoking inten-
ity (e.g., CO) is more likely to yield evidence of a
ose-response relationship than are self-reported smoking
ates (4,5). This is consistent with evidence that smokers
end to titrate their intake of nicotine by how intensively
nd efficiently they smoke each cigarette, which is reflected
Wy CO levels, as opposed to the number of cigarettes that
hey smoke each day (26).
tudy limitations. This was a randomized clinical trial of
moking cessation interventions, and thus there were no
onsmoking controls; therefore, we cannot determine the
xtent to which FMD approached normal values. The
tability of FMD among those who continued to smoke,
he similar FMD findings in each study arm, and the
ocumented reproducibility of FMD techniques in our
aboratory suggest that our findings are not due to chance
nd would not be seen in nonsmokers (20). Because FMD
as only measured at baseline and after 1 year, we could not
valuate the time course of FMD improvement with
uitting.
In smoking cessation studies, it is common for subjects
ho relapse to drop out or miss follow-up visits (27–29). In
ur study, 38.6% of subjects did not return for their 1-year
ollow-up FMD visit, which is consistent with the 30% to
3% 1-year dropout rates reported in other recent clinical
rials of smoking cessation pharmacotherapy (28,29). Sub-
ects who did not attend the follow-up visit were similar in
ge, sex, and race to those who did return, and they smoked
similar number of cigarettes/day at baseline. Although
heir baseline FMD was slightly lower, our findings were
obust in many analyses, and it is unlikely that their
nclusion would have changed our main finding: that smok-
ng cessation improves endothelial function. Second-hand
moke exposure was not quantified in this study. The
resence of second-hand smoke exposure may have led us to
nderestimate the effect of smoking cessation on FMD.
lthough significant efforts were made to recruit a racially
iverse subject population, nonwhites constituted only
bout 16% of the study cohort. Differences in the associa-
ions between smoking and endothelial function by race
ay not have been detected. We did not administer
itroglycerin, so an effect of smoking cessation that is not
ndothelium mediated cannot be excluded. Finally, the
ong-term effect of smoking cessation on CVD risk was not
valuated; however, data collection for a 3-year analysis of
arotid intima-media thickness is ongoing.
onclusions
n this large, prospective study of current smokers, smoking
ntensity was independently associated with endothelial
ysfunction. One year after smoking cessation, endothelial
unction improved significantly, despite weight gain. Im-
rovements in endothelial function may mediate some of
he reduced CVD risk observed after smoking cessation.
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